Krystal Biotech, Inc. KRYS R2KR3KPHARMA
Company Overview
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Why Investors Should Care
Generates a return on equity of 20.1%, reflecting efficient use of shareholder capital.
Maintains a net profit margin of 54.8%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $389.13M (+33.9% YoY); net profit $204.83M.
- Trailing 12 Months Year-on-year growth — revenue +24.1%, earnings +38.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 24.10% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 38.80% |
Stock Price Performance
| 1 Year: | +139.88% |
| 6 Months: | +41.21% |
| 3 Months: | +19.02% |
| 1 Month: | +11.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.87 · Neutral
P/E of 44.95 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 20.1%.
- Excellent profit margin of 54.8%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KRYS Krystal Biotech, Inc. R2KR3KPHARMA | 358.24 | 44.95 | $10.60B | 0.00% | 13.10% | 20.12% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 8.56M | 45.25M | 70.28M | 83.84M | 88.18M | 96.04M | 97.80M | 116.36M | 119.22M |
| Operating Income | -322.00K | -465.00K | -715.00K | -2.09M | -2.28M | -2.45M | -2.97M | -4.69M | -5.89M | -5.34M | -5.95M | -6.95M | -9.68M | -14.35M | -16.39M | -15.65M | -50.22M | -28.75M | -31.45M | -48.82M | -38.05M | -25.99M | -6.68M | 8.57M | 22.47M | 36.25M | 39.31M | 41.37M | 53.69M | 58.42M |
| Net Income | -322.00K | -494.00K | -759.00K | -5.27M | -2.15M | -2.28M | -2.75M | -4.11M | -5.35M | -4.27M | -5.34M | -6.83M | -9.61M | -15.81M | -16.36M | -15.59M | -49.97M | -28.11M | -29.85M | -45.30M | -33.21M | 80.75M | 932.00K | 15.57M | 27.18M | 35.73M | 38.33M | 79.36M | 55.93M | 54.77M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.37 | -0.49 | -0.74 | -0.74 | -0.70 | -1.99 | -1.10 | -1.17 | -1.76 | -1.25 | 2.79 | 0.03 | 0.53 | 0.91 | 1.20 | 1.29 | 2.66 | 1.83 | 1.79 |
| R&D Expense | 241.00K | 319.00K | 446.00K | 1.35M | 1.52M | 1.52M | 1.91M | 3.17M | 4.22M | 3.88M | 3.52M | 3.64M | 5.10M | 6.20M | 6.59M | 6.08M | 9.31M | 10.89M | 11.52M | 12.29M | 12.14M | 10.63M | 10.96M | 15.58M | 13.51M | 14.26M | 14.41M | 14.59M | 15.33M | 14.52M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 50.70M | 290.51M | 389.13M |
| Operating Income | -1.14M | -4.77M | -11.92M | -22.08M | -33.00M | -68.28M | -145.20M | -109.62M | 65.75M | 161.29M |
| Net Income | -1.15M | -7.92M | -10.89M | -19.09M | -32.17M | -69.57M | -139.97M | 10.93M | 89.16M | 204.83M |
| Diluted EPS | - | - | - | - | -1.71 | -3.13 | -5.49 | 0.39 | 3.00 | 6.84 |
| R&D Expense | 741.00K | 3.21M | 7.76M | 15.62M | 17.94M | 27.88M | 42.46M | 46.43M | 53.58M | 58.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Aug 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 2.18M | - | 50.11M | 116.12M | 209.02M | 310.84M | - | 558.45M | 818.36M | 1.06B | 1.33B |
| Current Assets | - | - | - | - | - | - | - | 383.78M | 587.91M | 742.04M | 1.02B |
| Cash & Equivalents | 1.92M | - | 49.59M | 103.67M | 187.51M | 268.27M | - | 161.90M | 358.33M | 344.87M | 496.30M |
| Inventory | - | - | - | - | - | - | - | 0 | 6.99M | 26.51M | 40.48M |
| Receivables | - | - | - | - | - | - | - | 0 | 42.04M | 104.75M | 127.42M |
| Total Liabilities | 1.89M | - | 640.00K | 2.89M | 6.11M | 18.76M | - | 36.22M | 39.71M | 109.46M | 114.23M |
| Current Liabilities | 43.00K | - | 640.00K | 2.60M | 3.33M | 15.45M | - | 28.85M | 33.09M | 102.00M | 102.94M |
| Long Term Debt | - | 4.25M | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 8.93M | 8.09M | 7.26M | 9.34M |
| Total Equity | 289.00K | - | 49.47M | 113.23M | 202.91M | 292.08M | - | 522.23M | 778.64M | 946.38M | 1.22B |
| Shares Outstanding | - | - | - | - | - | - | - | 25.76M | 28.24M | 28.79M | 29.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -9.45M | -18.69M | -26.08M | -47.94M | -100.57M | -88.80M | 123.42M | 200.87M |
| Investing Cash Flow | - | - | -10.32M | -4.99M | -11.18M | -226.77M | -114.08M | 82.64M | -163.44M | -58.42M |
| Financing Cash Flow | - | - | 73.85M | 107.53M | 118.02M | 347.69M | 35.35M | 202.75M | 27.01M | 8.71M |
| Capital Expenditure | -15.00K | -210.00K | -2.23M | -6.40M | -14.84M | -68.34M | -52.98M | -11.80M | -4.24M | -11.95M |
| Free Cash Flow | - | - | -11.68M | -25.09M | -40.93M | -116.27M | -153.55M | -100.60M | 119.18M | 188.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -216.2% | 22.6% | 41.5% |
| Net Margin % | - | - | - | - | - | - | - | 21.6% | 30.7% | 52.6% |
| ROE % | -397.9% | -16.0% | -9.6% | -9.4% | -11.0% | - | -26.8% | 1.4% | 9.4% | 16.8% |
| ROCE % | -53.4% | -9.6% | -10.5% | -10.7% | -11.2% | - | -27.4% | -14.0% | 6.9% | 13.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.93% | 4.42M | $1.55B |
| 2 | Blackrock Inc. | 14.13% | 4.18M | $1.47B |
| 3 | Avoro Capital Advisors LLC | 9.76% | 2.89M | $1.02B |
| 4 | Vanguard Portfolio Management LLC | 5.32% | 1.57M | $553.52M |
| 5 | State Street Corporation | 4.56% | 1.35M | $474.88M |
| 6 | Vanguard Capital Management LLC | 4.19% | 1.24M | $436.01M |
| 7 | Soleus Capital Management, L.P. | 3.17% | 939.25K | $330.11M |
| 8 | Capital World Investors | 2.63% | 777.84K | $273.38M |
| 9 | Geode Capital Management, LLC | 2.36% | 698.99K | $245.67M |
| 10 | Price (T.Rowe) Associates Inc | 2.32% | 687.40K | $241.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KRYS
Krystal Biotech (KRYS) Stock Looks Fully Valued on Future Earnings Hopes - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQT2NKOU9EaFZrOWtzcFZVV2hyTW9LLXE0a0xDTmFJTWNrNnVUaXBvZnI0a3dQdG9kbjNhYzJfckw5cnM5TklOVDA5bWhxWC16ZUhTOVJfOG5tcmVtcDZKWFNyd05aTEhRRmljY0RJdmIyS2dOZ1RrdTdDelR5WDVCd3NRMVcxZG4yYkJaMW…
Insider Sale: President of $KRYS Sells 1,992 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOaFUxMk5RLTlZTnlGamhsVGdBRmd2ckIzblRhVFZzV0NLSlU0XzFuSzAxUFpWSXZWQW9qZk1yd09NaU5GbTB3enVFc2FleHVPQ2xRRVZmZl8tVlo1d1JGMlo1UERPMjRWUjFtcFFRX1lwQm5qWXRmbmd4WUFXUms2eVctSXJLOXhpLThsQ0…
Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOSy1EWmRXQlVNVDZBWi1hdkxsdGRhbmZiOHBibEdzTWx2dXdHTWxBS2ctQ3FSSlE2NHhTTGZKa0JhLVlIU09LaTJiRzFsOXNJc3dpUURaQ2NQeU9PMS13T1o4blQyc0c0V2ozRlFqLU9IQlJQeG5kMlp2Tl9WYXBaekhnc1Jhd0taWEE2Nm…
A healthcare conference webcast is set for Sept. 10 in New York - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOVnJBeTFrM1hka3R3d1dMTjI5S3hhM3NHVGQxWEo0d1BZTHBXWWhidV9EckVJblZWRy1TTDNWVld1YjhUUWV0eHFXWGhvNDkzLXpjMHNzeDNfNFAteWdKZGJXTmZKcXhLYXdiZDd2RzczTm5kbVJyMnhKcVRSMzJtdWZ0SnY2RldaYmpNSF…
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxORXlqNzBSZnlJN3l1eWR1Q0FBWXNHV2w5NWg2SmFIVFV6YmpRQjRVMUF0NWJQcmxxQ2M4QmdlQ2dyT1kxME5HRnV5dk1ISkVFbm9GYWZiem9yN1N3WWpKN0JEM1ZMM1pzeWNvV3E4Y3BzZHY2Uk9pMlNQSGRiSl9qVEI2NkpZT0dQUnFpVT…
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - TradingView
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNWi0yV1BhZ3lTN05RbFZUM0otdDZURXU0c3JId2FqbGRFNW1tTVhUQWhnLTk5QzBNU09DSW5uUG01aE00MElyYXVNdEM2YkdDOTVQcEh2b2ZkNU9iaHo2V2pEX1lHdFJJR1Q3U0Y1Yi1hQV9ORWdnaXFreXl1SlNFSG5qTUtPZVZhdy1kaz…
KRYS — Frequently Asked Questions
What is the current share price of Krystal Biotech, Inc. (KRYS)?
As of 2026-09-07 16:24 PDT, Krystal Biotech, Inc. (KRYS) trades at $358.24 on NasdaqGS. Its 52-week range is $137.46 to $378.15.
What is the market capitalisation of KRYS?
Krystal Biotech, Inc. (KRYS) has a market capitalisation of $10.60B on NasdaqGS.
What is the P/E ratio of KRYS?
KRYS trades at a trailing price-to-earnings (P/E) ratio of 44.95. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.53.
What is the return on equity (ROE) of KRYS?
KRYS has a return on equity (ROE) of 20.12%. Its return on capital employed (ROCE) is 13.10%.
Is KRYS a good stock to buy?
This page provides a data-driven analysis of Krystal Biotech, Inc. (KRYS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.